Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review

Gut Microbes

Volumn 8, Issue 3, 2017, Pages 225-237

  Woodworth, Michael H ^a   Carpentieri, Cynthia ^a   Sitchenko, Kaitlin L ^a   Kraft, Colleen S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

antibiotic resistance; Clostridium difficile; fecal microbiota transplantation; FMT; gut microbial therapeutics; microbiome; resistome; stool donor screening

Indexed keywords

ANTIBIOTIC RESISTANCE; ASYMPTOMATIC DISEASE; BLASTOCYSTIS; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL TUMOR; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DONOR; ENTEROBACTERIACEAE; ENZYME IMMUNOASSAY; FECAL DONOR; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; INTESTINE FLORA; METABOLIC DISORDER; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; OBESITY; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; REVIEW; TRIPLE FECES TEST; CLOSTRIDIUM INFECTION; DONOR SELECTION; DRUG EFFECTS; FECES; FOOD AND DRUG ADMINISTRATION; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; UNITED STATES;

CLOSTRIDIUM INFECTIONS; DONOR SELECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; METABOLIC DISEASES; OBESITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85020516094     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.1080/19490976.2017.1286006     Document Type: Review

References (69)

1. Dubberke ER, Olsen MA. Burden of clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55:88-92; http://dx.doi.org/10.1093/cid/cis335
2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med [Internet] 2015; 372:825-34. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25714160; PMID:25714160; http://dx.doi.org/10.1056/NEJMoa1408913
3. Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection. Ann Intern Med [Internet] 2016; 165(9):609-616; Available from:http://annals.org/article.aspx?; PMID:27547925; http://dx.doi.org/10.7326/M16-0271
4. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med [Internet] 2013; 368:407-15. Available from:http://www.ncbi.nlm.nih.gov/pubmed/23323867; PMID:23323867; http://dx.doi.org/10.1056/NEJMoa1205037
5. Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, Sanguinetti M, Gasbarrini A. Randomised clinical trial:faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther [Internet] 2015; 41(9):835-43; [Epub ahead of print]. Available from:http://doi.wiley.com/10.1111/apt.13144; PMID:25728808; http://dx.doi.org/10.1111/apt.13144
6. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002; PMID:22002980; http://dx.doi.org/10.1093/cid/cir632
7. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol [Internet] 2012; 107:1755; author reply p.1755-p.6. Available from:http://www.ncbi.nlm.nih.gov/pubmed/23160295%5Cnhttp://dx.doi.org/10.1038/ajg.2012.251; PMID:23160295; http://dx.doi.org/10.1038/ajg.2012.251
8. National Library of Medicine (US). ClinicalTrials.gov [Internet]. 2016 [cited 2016 Sep 1]; Available from:https://clinicaltrials.gov/ct2/results?termDfecalCtransplant&SearchDSearch
9. FDA. Guidance for industry enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat clostridium difficile infection not responsive to standard therapies [Internet]. 2014 [cited 2016 Sep 1]; Available from:http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM387255.pdf
10. FDA. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat clostridium difficile infection not responsive to standard therapies. U.S Food and Drug Administration [Internet]. 2016. Available from:http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379.html
11. Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis [Internet] 2016; 10:387-94. Available from:http://ecco-jcc.oxfordjournals.org/; PMID:26519463; http://dx.doi.org/10.1093/ecco-jcc/jjv203
12. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology [Internet] 2015; 149:102-109.e6. Available from:http://dx.doi.org/10.1053/j.gastro.2015.04.001; PMID:25857665; http://dx.doi.org/10.1053/j.gastro.2015.04.001
13. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EMH, de Vos WM, et al. Findings from a randomized controlled trial of fecal transplantation for patients with Ulcerative Colitis. Gastroenterology [Internet] 2015; 149:110-118.e4. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25836986; PMID:25836986; http://dx.doi.org/10.1053/j.gastro.2015.03.045
14. Relman D, Vender RJ, Rustgi AK, Wang KK, Bousvaros A. Current consensus guidance on donor screening and stool testing for FMT. Bethesda, MD:American Gastroenterological Association; 2013. Available from:https://www.gastro.org/research/Joint_Society_FMT_Guidance.pdf
15. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol [Internet] 2011; 9:1044-9. Available from:http://dx.doi.org/10.1016/j.cgh.2011.08.014; PMID:21871249; http://dx.doi.org/10.1016/j.cgh.2011.08.014
16. Sachs RE, Edelstein CA. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation. J Law Biosci [Internet] 2015; 2:396-415. Available from:http://jlb.oxfordjournals.org/lookup/doi/10.1093/jlb/lsv032; PMID:27774199; http://dx.doi.org/10.1093/jlb/lsv032
17. Edelstein CA, Kassam Z, Daw J, Smith MB, Kelly CR. The regulation of fecal microbiota for transplantation:An international perspective for policy and public health. Clin Res Regul Aff [Internet] 2015; 32:101-9. Available from:http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2015341771; http://dx.doi.org/10.3109/10601333.2015.1046602
18. Smith MB, Kelly C, Alm EJ. Policy:How to regulate faecal transplants. Nature [Internet] 2014; 506:290-1. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24558658; PMID:24558658; http://dx.doi.org/10.1038/506290a
19. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015:Indications, methodologies, mechanisms, and outlook. Gastroenterology [Internet] 2015; 149:223-37. Available from:http://dx.doi.org/10.1053/j.gastro.2015.05.008; PMID:25982290; http://dx.doi.org/10.1053/j.gastro.2015.05.008
20. Burns LJ, Dubois N, Smith MB, Mendolia GM, Burgess J, Edelstein C, Noh A, Alm E, Kassam Z. 499 donor recruitment and eligibility for fecal microbiota transplantation:results from an international public stool bank. Gastroenterology [Internet] 2015; 148:S-96-S-97. Available from:http://linkinghub.elsevier.com/retrieve/pii/S0016508515303310
21. Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, van den Bogaerde J, Leong RWL, Connor S, Ng W, et al. Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis [Internet] 2015; 21:1600-6. Available from:http://www.ncbi.nlm.nih.gov/pubmed/26070003; PMID:26070003; http://dx.doi.org/10.1097/MIB.0000000000000405
22. Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, Rutks I, Wilt TJ. Fecal microbiota transplantation for clostridium difficile infection:A systematic review. Ann Intern Med [Internet] 2015; 162:630-8. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25938992; PMID:25938992; http://dx.doi.org/10.7326/M14-2693
23. Gathe JC, Diejomaoh EM, Mayberry CC, Clemmons JB. Fecal transplantation for Clostridium Difficile-“All stool may not be created equal.” J Int Assoc Provid AIDS Care [Internet] 2016; 15:107-8. Available from:http://www.ncbi.nlm.nih.gov/pubmed/26821578; PMID:26821578; http://dx.doi.org/10.1177/2325957415627695
24. Merenstein D, El-nachef N, Lynch S V. Fecal microbial therapy:promises and pitfalls. J Pediatr Gastroenterol Nutr [Internet]. 2014 Aug; 59(2):157-61. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24796803
25. Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic review:Adverse events of fecal microbiota transplantation. PLoS One [Internet] 2016; 11:e0161174. Available from:http://dx.plos.org/10.1371/journal.pone.0161174; PMID:27529553; http://dx.doi.org/10.1371/journal.pone.0161174
26. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, et al. Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for prevention of recurrent C difficile infection:A randomized clinical trial. Jama [Internet] 2015; 313:1719-27. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25942722; PMID:25942722; http://dx.doi.org/10.1001/jama.2015.3725
27. American Gastroenterological Association. AGA Establishes NIH-Funded Registry to Track Fecal Microbiota Transplants. [Internet]. Bethesda (MD):American Gastroenterological Association; 2016 Aug 4 [cited 2016 Aug 26]
28. Guh A, McDonald L. Containing what lies under thewaterline invited commentary invited commentary active surveillance and isolation of asymptomatic carriers of Clostridium difficile at hospital admission. JAMA Intern Med 2016; 176:1-2; PMID:27479247; http://dx.doi.org/10.1001/jamainternmed.2016.1118
29. Rossen NG, Bart A, Verhaar N, van Nood E, Kootte R, de Groot PF, D'Haens GR, Ponsioen CY, van Gool T. Low prevalence of Blastocystis sp. in active ulcerative colitis patients. Eur J Clin Microbiol Infect Dis [Internet] 2015; 34:1039-44. Available from:http://ecco-jcc.oxfordjournals.org/cgi/doi/10.1016/S1873-9946(14)60787-X; PMID:25680316; http://dx.doi.org/10.1007/s10096-015-2312-2
30. Andersen LOB. Blastocystis in Health and Disease Are we moving from a clinical to a public health perspective? PubMed Commons. J Clin Microbiol 2016; 54:524/8.
31. Audebert C, Even G, Cian A, Blastocystis Investigation Group, Loywick A, Merlin S, Viscogliosi E, Chabé M. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. Sci Rep [Internet] 2016; 6:25255. Available from:http://www.nature.com/articles/srep25255; PMID:27147260; http://dx.doi.org/10.1038/srep25255
32. Nourrisson C, Scanzi J, Pereira B, NkoudMongo C, Wawrzyniak I, Cian A, Viscogliosi E, Livrelli V, Delbac F, Dapoigny M, et al. Blastocystis is associated with decrease of fecal microbiota protective bacteria:comparative analysis between patients with irritable bowel syndrome and control subjects. PLoS One [Internet] 2014; 9:e111868. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4218853&tool=pmcentrez&rendertype=abstract; PMID:25365580; http://dx.doi.org/10.1371/journal.pone.0111868
33. Krogsgaard LR, Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome:A population-based case-control study. Clin Gastroenterol Hepatol 2015; 13:507-513.e2; PMID:25229421; http://dx.doi.org/10.1016/j.cgh.2014.07.065
34. Vennila GD, Suresh Kumar G, Khairul Anuar A, Rajah S, Saminathan R, Sivanandan S, Ramakrishnan K. Irregular shedding of Blastocystis hominis. Parasitol Res [Internet] 1999 [cited 2016 Nov 10]; 85:162-4. Available from:http://www.ncbi.nlm.nih.gov/pubmed/9934969; PMID:9934969; http://dx.doi.org/10.1007/s004360050528
35. Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg [Internet] 2010; 82:614-9. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2844584&tool=pmcentrez&rendertype=abstract; PMID:20348509; http://dx.doi.org/10.4269/ajtmh.2010.09-0478
36. Furuya-Kanamori L, Marquess J, Yakob L, Riley T V, Paterson DL, Foster NF, Huber CA, Clements ACA. Asymptomatic Clostridium difficile colonization:epidemiology and clinical implications. BMC Infect Dis [Internet] 2015; 15:516. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4647607&tool=pmcentrez&rendertype=abstract; PMID:26573915; http://dx.doi.org/10.1186/s12879-015-1258-4
37. Longtin Y, Paquet-Bolduc B, Gilca R, Garenc C, Fortin E, Longtin J, Trottier S, Gervais P, Roussy J-F, Lévesque S, et al. Effect of Detecting and Isolating Clostridium difficile Carriers at Hospital Admission on the Incidence of C difficile Infections:A Quasi-Experimental Controlled Study. JAMA Intern Med [Internet] 2016; 176:796-804. Available from:http://www.ncbi.nlm.nih.gov/pubmed/27111806; PMID:27111806; http://dx.doi.org/10.1001/jamainternmed.2016.0177
38. Stamper PD, Alcabasa R, Aird D, Babiker W, Wehrlin J, Ikpeama I, Carroll KC. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009; 47:373-8; PMID:19073875; http://dx.doi.org/10.1128/JCM.01613-08
39. Babady NE, Stiles J, Ruggiero P, Khosa P, Huang D, Shuptar S, Kamboj M, Kiehn TE. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol [Internet] 2010; 48:4519-24. Available from:http://www.ncbi.nlm.nih.gov/pubmed/20943860; PMID:20943860; http://dx.doi.org/10.1128/JCM.01648-10
40. Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, Nguyen HH, Huang B, Tang YW, Lee LW, et al. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med [Internet] 2015; 175:1-10. Available from:http://archinte.jamanetwork.com/article.aspx?articleid=2434732; http://dx.doi.org/10.1001/jamainternmed.2015.4114
41. Koo HL, Van JN, Zhao M, Ye X, Revell PA, Jiang Z-D, Grimes CZ, Koo DC, Lasco T, Kozinetz CA, et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol [Internet] 2014; 35:667-73. Available from:http://search.ebscohost.com/login.aspx?direct=true&db=jlh&AN=2012573261&site=ehost-live%5Cnhttp://www.jstor.org.ezp2.lib.umn.edu/stable/pdfplus/10.1086/676433.pdf; PMID:24799643; http://dx.doi.org/10.1086/676433
42. Buss SN, Leber A, Chapin K, Fey PD, Bankowski MJ, Jones MK, Rogatcheva M, Kanack KJ, Bourzac KM. Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. J Clin Microbiol 2015; 53:915-25; PMID:25588652; http://dx.doi.org/10.1128/JCM.02674-14
43. Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, et al. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy:PRIMERS I and II. Clin Infect Dis [Internet] 2016; 62:181-9. Available from:http://www.ncbi.nlm.nih.gov/pubmed/26409063; PMID:26409063; http://dx.doi.org/10.1093/cid/civ837
44. Pak TR, Kasarskis A. How Next-generation sequencing and multiscale data analysis will transform infectious disease management. Clin Infect Dis [Internet] 2015; 61:civ670. Available from:http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/civ670; http://dx.doi.org/10.1093/cid/civ670
45. Crum-Cianflone NF, Sullivan E, Ballon-Landa G. Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol 2015; 53:1986-9; PMID:25878340; http://dx.doi.org/10.1128/JCM.00820-15
46. Millan B, Park H, Hotte N, Mathieu O, Burguiere P, Tompkins TA, Kao D, Madsen KL. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis [Internet] 2016:1-9. Available from:http://www.ncbi.nlm.nih.gov/pubmed/27025836
47. Lesho EP, Clifford RJ. For rapid molecular detection, Why not a whole genome approach? Clin Infect Dis [Internet] 2016; 63:570-1. Available from:http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw332; PMID:27225237; http://dx.doi.org/10.1093/cid/ciw332
48. Evans S, Kreiswirth B, Fowler V, Chambers H, Patel R, Hujer AM, Perez F, Bonomo RA. Reply to Lesho and Clifford. Clin Infect Dis [Internet] 2016; 63:571-2. Available from:http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw336; PMID:27225238; http://dx.doi.org/10.1093/cid/ciw336
49. Halpin AL, McDonald LC. Editorial Commentary:The dawning of microbiome remediation for addressing antibiotic resistance. Clin Infect Dis [Internet] 2016; 62:1487-8. Available from:http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw187; PMID:27025827; http://dx.doi.org/10.1093/cid/ciw187
50. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. Fidaxomicin preserves the intestinal microbiome during and after treatment of clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55:132-42; http://dx.doi.org/10.1093/cid/cis338
51. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57:2326-32; PMID:23478961; http://dx.doi.org/10.1128/AAC.02176-12
52. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med [Internet] 2016; 8:39. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4831151&tool=pmcentrez&rendertype=abstract; PMID:27074706; http://dx.doi.org/10.1186/s13073-016-0294-z
53. Knecht H, Neulinger SC, Heinsen FA, Knecht C, Schilhabel A, Schmitz RA, Zimmermann A, dos Santos VM, Ferrer M, Rosenstiel PC, et al. Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PLoS One [Internet] 2014; 9:e89417. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24586762; PMID:24586762; http://dx.doi.org/10.1371/journal.pone.0089417
54. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, Gordon JI. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature [Internet] 2010; 466:334-8. Available from:http://dx.doi.org/10.1038/nature09199; PMID:20631792; http://dx.doi.org/10.1038/nature09199
55. Minot S, Bryson A. Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A [Internet] 2013; 110:12450-5. Available from:http://www.pnas.org/content/110/30/12450.short
56. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. Proc Natl Acad Sci [Internet] 2016; 113(37):10400-5.
57. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell [Internet] 2015; 160:447-60. Available from:http://dx.doi.org/10.1016/j.cell.2015.01.002; PMID:25619688; http://dx.doi.org/10.1016/j.cell.2015.01.002
58. Cui L, Morris A, Ghedin E. The human mycobiome in health and disease. Genome Med 2013; 5:1-12; PMID:23311897; http://dx.doi.org/10.1186/gm467
59. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open forum Infect Dis [Internet] 2015; 2:ofv004. Available from:http://ofid.oxfordjournals.org/content/early/2014/06/01/ofid.ofu038.short; PMID:26034755; http://dx.doi.org/10.1093/ofid/ofv004
60. Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Wilson Tang WH, Hazen SL. Intestinal Microbiota-Generated Metabolite Trimethylamine- N- Oxide and 5-year mortality risk in stable coronary artery disease:The contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc [Internet] 2016; 5:e002816. Available from:http://jaha.ahajournals.org/lookup/doi/10.1161/JAHA.115.002816; PMID:27287696; http://dx.doi.org/10.1161/JAHA.115.002816
61. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell [Internet] 2016; 165:111-24. Available from:http://dx.doi.org/10.1016/j.cell.2016.02.011; PMID:26972052; http://dx.doi.org/10.1016/j.cell.2016.02.011
62. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology [Internet] 2012; 143:913-916.e7. Available from:http://dx.doi.org/10.1053/j.gastro.2012.06.031; PMID:22728514; http://dx.doi.org/10.1053/j.gastro.2012.06.031
63. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe [Internet] 2014; 15:317-28. Available from:http://dx.doi.org/10.1016/j.chom.2014.02.007; PMID:24629338; http://dx.doi.org/10.1016/j.chom.2014.02.007
64. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, Peterson SN, Snesrud EC, Borisy GG, Lazarev M, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A [Internet] 2014; 111:18321-6. Available from:http://www.pnas.org/content/111/51/18321; PMID:25489084; http://dx.doi.org/10.1073/pnas.1406199111
65. Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res 2014; 7:1112-21; http://dx.doi.org/10.1158/1940-6207.CAPR-14-0129
66. Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer:microbial contributors to disease prevention, development and therapy. Br J Cancer [Internet] 2016; 115:273-80. Available from:http://www.nature.com/doifinder/10.1038/bjc.2016.189; PMID:27380134; http://dx.doi.org/10.1038/bjc.2016.189
67. Huse SM, Young VB, Morrison HG, Antonopoulos DA, Kwon J, Dalal S, Arrieta R, Hubert NA, Shen L, Vineis JH, et al. Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects. Microbiome [Internet] 2014; 2:5. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3931571&tool=pmcentrez&rendertype=abstract; PMID:24529162; http://dx.doi.org/10.1186/2049-2618-2-5
68. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science [Internet] 2005; 308:1635-8. Available from:http://www.ncbi.nlm.nih.gov/pubmed/15831718; PMID:15831718; http://dx.doi.org/10.1126/science.1110591
69. Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, Moris F, Rodrigo L, Mira A, Collado MC. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol [Internet] 2015; 50:167-79. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24811328; PMID:24811328; http://dx.doi.org/10.1007/s00535-014-0963-x